Previous
Next

Consistent Medication Release

Unique Technology: How QuilliChew ER provides consistent medication release

  • Our formulation of methylphenidate contains millions of microscopic delivery complexes1
  • The key to each complex is a special coating that protects methylphenidate and releases it consistently over time1
  • This protective layer makes sure your medication won’t be affected by the kind of food your child eats, for example, or differences in your child’s metabolism
  • Study Results
  • Pharmacokinetics (PK) describes the way in which a person’s body absorbs, distributes, metabolizes, and excretes a medication. The PK properties of QuilliChew ER were studied in healthy adults who were given 40 mg of QuilliChew ER compared to a methylphenidate immediate-release chewable tablet (IRCT), in two equal doses of 20 mg each, 6 hours apart. Blood samples were collected before and then at several time points after taking the drug. The amount of methylphenidate in each sample was then measured in a laboratory.
  • As shown in the chart below, blood levels of methylphenidate increased rapidly after taking QuilliChew ER, reaching a peak around 5 hours. Levels then gradually decreased from 5 hours through 24 hours.
  • Blood levels of methylphenidate in people who took the IR chewable tablet increased and decreased quickly. After a second dose of the IR chewable tablet, the blood levels again showed a quick rise and a quick drop off.

See more about QuilliChew ER's results in treating ADHD symptoms.

Mean methylphenidate plasma concentration-time profiles

QuilliChew ER Mean Methylphenidate Plasma Concentration-Time Profiles Graph

Did you know...?

QuilliChew ER has 11 different dosing options.

1 1/2 QuilliChew ER Tablets Icon
Learn about safety and side effects for QuilliChew ER

ERCT, extended-release chewable tablet.

Did you know you may be able to SAVE on a QuilliChew ER prescription?**

Eligible patients may
pay as little as $25
Get savings card
Or text TRIS to TRIS4U (874748) for a Mobile Savings Card.
ADHD Teen Friends Smiling #2

* Co-pay offer is subject to eligibility. Terms and Conditions apply.

Mobile Terms and Conditions: coupon.trisadhd.com/terms. Message data rates may apply.

References: 1. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 2021. 2. QuilliChew ER [package insert]. Tris Pharma, Inc., Monmouth Junction, NJ.

Important Safety Information & Approved Use

DYANAVEL® XR (amphetamine), Quillivant XR® (methylphenidate HCI), and QuilliChew ER® (methylphenidate HCI) are federally controlled substances (CII) because they can be a target for people who abuse prescription medicines or street drugs. DYANAVEL XR, Quillivant XR, and QuilliChew ER have a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep these medicines in a safe place to prevent abuse and misuse. Selling or giving away these medicines may harm others and is against the law. Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with DYANAVEL XR, Quillivant XR, and QuilliChew ER and will monitor you or your child during treatment. Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

See Additional Important Safety Information.

Important Safety Information & Approved Use

DYANAVEL® XR (amphetamine), Quillivant XR® (methylphenidate HCl), and QuilliChew ER® (methylphenidate HCl) are federally controlled substances (CII) because they can be a target for people who abuse prescription medicines or street drugs. DYANAVEL XR, Quillivant XR, and QuilliChew ER have a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep these medicines in a safe place to prevent abuse and misuse. Selling or giving away these medicines may harm others and is against the law.

Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with DYANAVEL XR, Quillivant XR, and QuilliChew ER and will monitor you or your child during treatment. Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

DYANAVEL XR, or Quillivant XR and QuilliChew ER, should not be taken if you or your child are allergic to amphetamine or methylphenidate hydrochloride, respectively, or any of the ingredients in these medicines, or are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI including the antibiotic linezolid and the intravenous medicine methylene blue.

DYANAVEL XR, Quillivant XR, and QuilliChew ER can cause serious side effects. Tell the doctor:

  • if you or your child have heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in children 6 to 17 years old with heart problems or defects, and sudden death, stroke, and heart attack have happened in adults. Your doctor should check you or your child carefully for heart problems before starting any of these medicines. Call the doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking any of these medicines.
  • Since increases in blood pressure and heart rate may occur, the doctor should regularly check these during treatment.
  • if you or your child have mental problems, or a family history of suicide, bipolar illness, or depression. This is important because new or worsening behavior and thought problems or bipolar illness may occur. New symptoms such as seeing or hearing things that are not real, believing things that are not true, being suspicious, or having new manic symptoms may occur. Call the doctor right away if there are any new or worsening mental symptoms during treatment.
  • if you or your child have circulation problems in fingers and toes (called peripheral vasculopathy, including Raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature, and/or change color from pale, to blue, to red. Call the doctor right away if any signs of unexplained wounds appear on fingers or toes while taking DYANAVEL XR, Quillivant XR, or QuilliChew ER.
  • if your child is having slowing of growth (height and weight); Your child should have his or her height and weight checked often while taking DYANAVEL XR, Quillivant XR, or QuilliChew ER.
  • New or worsening tics or worsening Tourette’s syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment.
  • There have been cases of increased eye pressure and acute angle closure glaucoma, an emergency that results from a rapid increase in your eye pressure with Quillivant XR and QuilliChew ER. Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.
  • if you or your child develop painful and prolonged erections (priapism), seek medical help right away. Priapism has occurred with methylphenidate (Quillivant XR and QuilliChew ER). Because priapism can cause long-lasting damage, it should be checked by a doctor right away.
  • if you or your child have symptoms of serotonin syndrome - agitation, hallucinations, coma, or other changes in mental status; fast heartbeat; sweating or fever; nausea, vomiting, diarrhea; high or low blood pressure; problems controlling movements or muscle twitching; muscle stiffness or tightness. Serotonin syndrome may occur when DYANAVEL XR is taken with certain other medicines and may be life-threatening. Stop DYANAVEL XR and call your doctor or go to the nearest hospital emergency room.
  • if you or your child have phenylketonuria (PKU). QuilliChew ER contains phenylalanine as part of the artificial sweetener, aspartame. The artificial sweetener may be harmful to people with PKU or who are allergic to phenylalanine.
  • if you or your child are pregnant or plan to become pregnant. It is not known if DYANAVEL XR, Quillivant XR, or QuilliChew ER will harm your unborn baby. There is a pregnancy registry for females who are exposed to DYANAVEL XR, Quillivant XR, or QuilliChew ER during pregnancy. The purpose of the registry is to collect information about the health of females exposed to DYANAVEL XR, Quillivant XR, or QuilliChew ER and their baby. If you or your child becomes pregnant during treatment with DYANAVEL XR, Quillivant XR, or QuilliChew ER, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visit https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
  • You and your child should not breastfeed while you are taking DYANAVEL XR. You and your healthcare provider should decide if you will take Quillivant XR or QuilliChew ER or breastfeed.

Common side effects of amphetamine products include:

  • dry mouth
  • nausea
  • extreme mood changes
  • decreased appetite
  • trouble sleeping
  • dizziness
  • weight loss
  • restlessness
  • increased heart rate
  • stomach pain

Common side effects of methylphenidate products inlude:

  • decreased appetite
  • stomach pain
  • irritability
  • trouble sleeping
  • weight loss
  • mood swings
  • nausea
  • anxiety
  • fast heart beat
  • vomiting
  • dizziness
  • increased blood pressure
  • indigestion

Talk to your doctor if you or your child have any side effects that bother you or do not go away.

Avoid drinking alcohol while taking DYANAVEL XR, Quillivant XR, or QuilliChew ER.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

APPROVED USE

DYANAVEL XR, Quillivant XR, and QuilliChew ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older. These medicines may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if DYANAVEL XR, Quillivant XR, and QuilliChew ER are safe and effective in children under 6 years of age.

See Medication Guide for DYANAVEL XR, Quillivant XR, and QuilliChew ER.

See Full Prescribing Information for DYANAVEL XR, Quillivant XR, and QuilliChew ER, including Boxed Warning about Abuse, Misuse and Addiction.

up arrowTop